{
  "name": "Regulatory status of research peptides",
  "description": "For each research compound in the Primara Labs catalogue: status with FDA Philippines, the US FDA and the EMA, and the sponsor's stated next milestone, each sourced and dated.",
  "source": "https://www.primaralabs.com/research/status",
  "lastUpdated": "2026-09-23",
  "licence": "Free to reuse with a link to the source page.",
  "schema": [
    {
      "key": "compound",
      "type": "string",
      "description": "Compound name."
    },
    {
      "key": "compoundId",
      "type": "string",
      "description": "Anchor on /research/status."
    },
    {
      "key": "fdaPh",
      "type": "string",
      "description": "FDA Philippines: \"Not approved\", \"Approved for <indication>\", \"Investigational\" or \"No record found\"; empty when it could not be established."
    },
    {
      "key": "fdaPhNote",
      "type": "string",
      "description": "Why a value is empty, or what the record covers."
    },
    {
      "key": "fdaPhSourceUrl",
      "type": "url",
      "description": "The record the status was read from."
    },
    {
      "key": "fdaPhCheckedOn",
      "type": "date",
      "description": "ISO date the record was read."
    },
    {
      "key": "usFda",
      "type": "string",
      "description": "US FDA: \"Not approved\", \"Approved for <indication>\", \"Investigational\" or \"No record found\"; empty when it could not be established."
    },
    {
      "key": "usFdaNote",
      "type": "string",
      "description": "Why a value is empty, or what the record covers."
    },
    {
      "key": "usFdaSourceUrl",
      "type": "url",
      "description": "The record the status was read from."
    },
    {
      "key": "usFdaCheckedOn",
      "type": "date",
      "description": "ISO date the record was read."
    },
    {
      "key": "ema",
      "type": "string",
      "description": "EMA: \"Not approved\", \"Approved for <indication>\", \"Investigational\" or \"No record found\"; empty when it could not be established."
    },
    {
      "key": "emaNote",
      "type": "string",
      "description": "Why a value is empty, or what the record covers."
    },
    {
      "key": "emaSourceUrl",
      "type": "url",
      "description": "The record the status was read from."
    },
    {
      "key": "emaCheckedOn",
      "type": "date",
      "description": "ISO date the record was read."
    },
    {
      "key": "nextMilestone",
      "type": "string",
      "description": "Next milestone: \"Not approved\", \"Approved for <indication>\", \"Investigational\" or \"No record found\"; empty when it could not be established."
    },
    {
      "key": "nextMilestoneNote",
      "type": "string",
      "description": "Why a value is empty, or what the record covers."
    },
    {
      "key": "nextMilestoneSourceUrl",
      "type": "url",
      "description": "The record the status was read from."
    },
    {
      "key": "nextMilestoneCheckedOn",
      "type": "date",
      "description": "ISO date the record was read."
    },
    {
      "key": "sourceUrl",
      "type": "url",
      "description": "The primary source the row was read from."
    },
    {
      "key": "checkedOn",
      "type": "date",
      "description": "ISO date the source was last read."
    }
  ],
  "rowCount": 16,
  "rows": [
    {
      "compound": "Retatrutide",
      "compoundId": "retatrutide",
      "fdaPh": null,
      "fdaPhNote": "Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.",
      "fdaPhSourceUrl": null,
      "fdaPhCheckedOn": null,
      "usFda": "Investigational",
      "usFdaNote": "Eli Lilly's release of 23 July 2026 describes retatrutide as investigational. Drugs@FDA returned no approved application.",
      "usFdaSourceUrl": "https://lilly.mediaroom.com/2026-07-23-Lillys-triple-agonist,-retatrutide,-successful-in-two-additional-Phase-3-obesity-trials,-delivering-significant-improvements-in-weight-and-A1C",
      "usFdaCheckedOn": "2026-09-23",
      "ema": "No record found",
      "emaNote": "No row for this substance in the EMA medicines report generated 22 September 2026. That report does not cover national authorisations in EU member states.",
      "emaSourceUrl": "https://www.ema.europa.eu/en/documents/report/medicines-output-medicines-report_en.xlsx",
      "emaCheckedOn": "2026-09-23",
      "nextMilestone": "Sponsor plans a US Biologics License Application submission in Q1 2027",
      "nextMilestoneNote": "Eli Lilly press release dated 23 July 2026.",
      "nextMilestoneSourceUrl": "https://lilly.mediaroom.com/2026-07-23-Lillys-triple-agonist,-retatrutide,-successful-in-two-additional-Phase-3-obesity-trials,-delivering-significant-improvements-in-weight-and-A1C",
      "nextMilestoneCheckedOn": "2026-09-23",
      "sourceUrl": "https://lilly.mediaroom.com/2026-07-23-Lillys-triple-agonist,-retatrutide,-successful-in-two-additional-Phase-3-obesity-trials,-delivering-significant-improvements-in-weight-and-A1C",
      "checkedOn": "2026-09-23"
    },
    {
      "compound": "Tirzepatide",
      "compoundId": "tirzepatide",
      "fdaPh": null,
      "fdaPhNote": "Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.",
      "fdaPhSourceUrl": null,
      "fdaPhCheckedOn": null,
      "usFda": "Approved for glycemic control in type 2 diabetes mellitus (Mounjaro); weight reduction in obesity or overweight with a comorbidity and moderate to severe obstructive sleep apnea in adults with obesity (Zepbound)",
      "usFdaNote": "Drugs@FDA: Mounjaro (NDA215866, approved 13 May 2022); Zepbound (NDA217806, approved 8 November 2023). The approval covers the named branded medicine for its labelled use only, never a research-grade vial of the same substance.",
      "usFdaSourceUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215866",
      "usFdaCheckedOn": "2026-09-23",
      "ema": "Approved for type 2 diabetes mellitus and weight management (Mounjaro)",
      "emaNote": "Mounjaro, EMEA/H/C/005620, authorised 15 September 2022. The authorisation covers the named medicine only.",
      "emaSourceUrl": "https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro",
      "emaCheckedOn": "2026-09-23",
      "nextMilestone": null,
      "nextMilestoneNote": "None sought: an approved medicine already exists.",
      "nextMilestoneSourceUrl": null,
      "nextMilestoneCheckedOn": null,
      "sourceUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215866",
      "checkedOn": "2026-09-23"
    },
    {
      "compound": "Semaglutide",
      "compoundId": "semaglutide",
      "fdaPh": null,
      "fdaPhNote": "Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.",
      "fdaPhSourceUrl": null,
      "fdaPhCheckedOn": null,
      "usFda": "Approved for glycemic control in type 2 diabetes mellitus and related cardiovascular and kidney risk reduction (Ozempic, Rybelsus); chronic weight management and cardiovascular risk reduction in obesity or overweight (Wegovy)",
      "usFdaNote": "Drugs@FDA: Ozempic (NDA209637, approved 5 December 2017); WEGOVY (injection) (NDA215256, approved 4 June 2021); RYBELSUS / OZEMPIC (tablets) (NDA213051, approved 20 September 2019); Rybelsus (NDA213182, approved 16 January 2020); WEGOVY (tablets) (NDA218316, approved 22 December 2025). The approval covers the named branded medicine for its labelled use only, never a research-grade vial of the same substance.",
      "usFdaSourceUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209637",
      "usFdaCheckedOn": "2026-09-23",
      "ema": "Approved for type 2 diabetes mellitus (Ozempic, Rybelsus), weight management (Wegovy) and non-cirrhotic MASH with F2 to F3 fibrosis (Kayshild)",
      "emaNote": "Five authorised products containing semaglutide, all held by Novo Nordisk A/S. The authorisation covers the named medicines only.",
      "emaSourceUrl": "https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic",
      "emaCheckedOn": "2026-09-23",
      "nextMilestone": null,
      "nextMilestoneNote": "None sought: an approved medicine already exists.",
      "nextMilestoneSourceUrl": null,
      "nextMilestoneCheckedOn": null,
      "sourceUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209637",
      "checkedOn": "2026-09-23"
    },
    {
      "compound": "BPC-157",
      "compoundId": "bpc-157",
      "fdaPh": null,
      "fdaPhNote": "Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.",
      "fdaPhSourceUrl": null,
      "fdaPhCheckedOn": null,
      "usFda": "No record found",
      "usFdaNote": "Drugs@FDA returned no approved or tentatively approved application for this substance. Drugs@FDA does not list investigational products. Separately, the FDA lists it on its page of bulk drug substances for compounding that may present significant safety risks (current as of 22 April 2026); that page concerns compounding, not approval.",
      "usFdaSourceUrl": "https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22BPC-157%22&limit=10",
      "usFdaCheckedOn": "2026-09-23",
      "ema": "No record found",
      "emaNote": "No row for this substance in the EMA medicines report generated 22 September 2026. That report does not cover national authorisations in EU member states.",
      "emaSourceUrl": "https://www.ema.europa.eu/en/documents/report/medicines-output-medicines-report_en.xlsx",
      "emaCheckedOn": "2026-09-23",
      "nextMilestone": null,
      "nextMilestoneNote": "No sponsor identified in any record read.",
      "nextMilestoneSourceUrl": null,
      "nextMilestoneCheckedOn": null,
      "sourceUrl": "https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22BPC-157%22&limit=10",
      "checkedOn": "2026-09-23"
    },
    {
      "compound": "TB-500",
      "compoundId": "tb-500",
      "fdaPh": null,
      "fdaPhNote": "Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.",
      "fdaPhSourceUrl": null,
      "fdaPhCheckedOn": null,
      "usFda": "No record found",
      "usFdaNote": "Drugs@FDA returned no approved or tentatively approved application for this substance. Drugs@FDA does not list investigational products. Separately, the FDA lists it on its page of bulk drug substances for compounding that may present significant safety risks (current as of 22 April 2026); that page concerns compounding, not approval.",
      "usFdaSourceUrl": "https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22thymosin%20beta-4%22&limit=10",
      "usFdaCheckedOn": "2026-09-23",
      "ema": "No record found",
      "emaNote": "No row for this substance in the EMA medicines report generated 22 September 2026. That report does not cover national authorisations in EU member states.",
      "emaSourceUrl": "https://www.ema.europa.eu/en/documents/report/medicines-output-medicines-report_en.xlsx",
      "emaCheckedOn": "2026-09-23",
      "nextMilestone": null,
      "nextMilestoneNote": "No sponsor identified in any record read.",
      "nextMilestoneSourceUrl": null,
      "nextMilestoneCheckedOn": null,
      "sourceUrl": "https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22thymosin%20beta-4%22&limit=10",
      "checkedOn": "2026-09-23"
    },
    {
      "compound": "GHK-Cu",
      "compoundId": "ghk-cu",
      "fdaPh": null,
      "fdaPhNote": "Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.",
      "fdaPhSourceUrl": null,
      "fdaPhCheckedOn": null,
      "usFda": "No record found",
      "usFdaNote": "Drugs@FDA returned no approved or tentatively approved application for this substance. Drugs@FDA does not list investigational products. Separately, the FDA lists it on its page of bulk drug substances for compounding that may present significant safety risks (current as of 22 April 2026); that page concerns compounding, not approval.",
      "usFdaSourceUrl": "https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22GHK-Cu%22&limit=10",
      "usFdaCheckedOn": "2026-09-23",
      "ema": "No record found",
      "emaNote": "No row for this substance in the EMA medicines report generated 22 September 2026. That report does not cover national authorisations in EU member states.",
      "emaSourceUrl": "https://www.ema.europa.eu/en/documents/report/medicines-output-medicines-report_en.xlsx",
      "emaCheckedOn": "2026-09-23",
      "nextMilestone": null,
      "nextMilestoneNote": "No sponsor identified in any record read.",
      "nextMilestoneSourceUrl": null,
      "nextMilestoneCheckedOn": null,
      "sourceUrl": "https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22GHK-Cu%22&limit=10",
      "checkedOn": "2026-09-23"
    },
    {
      "compound": "KPV",
      "compoundId": "kpv",
      "fdaPh": null,
      "fdaPhNote": "Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.",
      "fdaPhSourceUrl": null,
      "fdaPhCheckedOn": null,
      "usFda": "No record found",
      "usFdaNote": "Drugs@FDA returned no approved or tentatively approved application for this substance. Drugs@FDA does not list investigational products. Separately, the FDA lists it on its page of bulk drug substances for compounding that may present significant safety risks (current as of 22 April 2026); that page concerns compounding, not approval.",
      "usFdaSourceUrl": "https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22KPV%22&limit=10",
      "usFdaCheckedOn": "2026-09-23",
      "ema": "No record found",
      "emaNote": "No row for this substance in the EMA medicines report generated 22 September 2026. That report does not cover national authorisations in EU member states.",
      "emaSourceUrl": "https://www.ema.europa.eu/en/documents/report/medicines-output-medicines-report_en.xlsx",
      "emaCheckedOn": "2026-09-23",
      "nextMilestone": null,
      "nextMilestoneNote": "No sponsor identified in any record read.",
      "nextMilestoneSourceUrl": null,
      "nextMilestoneCheckedOn": null,
      "sourceUrl": "https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22KPV%22&limit=10",
      "checkedOn": "2026-09-23"
    },
    {
      "compound": "NAD+",
      "compoundId": "nad",
      "fdaPh": null,
      "fdaPhNote": "Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.",
      "fdaPhSourceUrl": null,
      "fdaPhCheckedOn": null,
      "usFda": "No record found",
      "usFdaNote": "Drugs@FDA returned no approved or tentatively approved application for this substance. Drugs@FDA does not list investigational products.",
      "usFdaSourceUrl": "https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22NAD%22&limit=10",
      "usFdaCheckedOn": "2026-09-23",
      "ema": "No record found",
      "emaNote": "No row for this substance in the EMA medicines report generated 22 September 2026. That report does not cover national authorisations in EU member states.",
      "emaSourceUrl": "https://www.ema.europa.eu/en/documents/report/medicines-output-medicines-report_en.xlsx",
      "emaCheckedOn": "2026-09-23",
      "nextMilestone": null,
      "nextMilestoneNote": "No sponsor identified in any record read.",
      "nextMilestoneSourceUrl": null,
      "nextMilestoneCheckedOn": null,
      "sourceUrl": "https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22NAD%22&limit=10",
      "checkedOn": "2026-09-23"
    },
    {
      "compound": "MOTS-c",
      "compoundId": "mots-c",
      "fdaPh": null,
      "fdaPhNote": "Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.",
      "fdaPhSourceUrl": null,
      "fdaPhCheckedOn": null,
      "usFda": "No record found",
      "usFdaNote": "Drugs@FDA returned no approved or tentatively approved application for this substance. Drugs@FDA does not list investigational products. Separately, the FDA lists it on its page of bulk drug substances for compounding that may present significant safety risks (current as of 22 April 2026); that page concerns compounding, not approval.",
      "usFdaSourceUrl": "https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22MOTS-c%22&limit=10",
      "usFdaCheckedOn": "2026-09-23",
      "ema": "No record found",
      "emaNote": "No row for this substance in the EMA medicines report generated 22 September 2026. That report does not cover national authorisations in EU member states.",
      "emaSourceUrl": "https://www.ema.europa.eu/en/documents/report/medicines-output-medicines-report_en.xlsx",
      "emaCheckedOn": "2026-09-23",
      "nextMilestone": null,
      "nextMilestoneNote": "No sponsor identified in any record read.",
      "nextMilestoneSourceUrl": null,
      "nextMilestoneCheckedOn": null,
      "sourceUrl": "https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22MOTS-c%22&limit=10",
      "checkedOn": "2026-09-23"
    },
    {
      "compound": "Tesamorelin",
      "compoundId": "tesamorelin",
      "fdaPh": null,
      "fdaPhNote": "Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.",
      "fdaPhSourceUrl": null,
      "fdaPhCheckedOn": null,
      "usFda": "Approved for reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy",
      "usFdaNote": "Drugs@FDA: Egrifta (BLA022505, approved 10 November 2010). The approval covers the named branded medicine for its labelled use only, never a research-grade vial of the same substance.",
      "usFdaSourceUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022505",
      "usFdaCheckedOn": "2026-09-23",
      "ema": "Not approved",
      "emaNote": "The application for Egrifta (EMEA/H/C/002427) was withdrawn on 21 June 2012; no marketing authorisation was granted.",
      "emaSourceUrl": "https://www.ema.europa.eu/en/medicines/human/EPAR/egrifta",
      "emaCheckedOn": "2026-09-23",
      "nextMilestone": null,
      "nextMilestoneNote": "None sought: an approved medicine already exists.",
      "nextMilestoneSourceUrl": null,
      "nextMilestoneCheckedOn": null,
      "sourceUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022505",
      "checkedOn": "2026-09-23"
    },
    {
      "compound": "CJC-1295",
      "compoundId": "cjc-1295",
      "fdaPh": null,
      "fdaPhNote": "Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.",
      "fdaPhSourceUrl": null,
      "fdaPhCheckedOn": null,
      "usFda": "No record found",
      "usFdaNote": "Drugs@FDA returned no approved or tentatively approved application for this substance. Drugs@FDA does not list investigational products. Separately, the FDA lists it on its page of bulk drug substances for compounding that may present significant safety risks (current as of 22 April 2026); that page concerns compounding, not approval.",
      "usFdaSourceUrl": "https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22CJC-1295%22&limit=10",
      "usFdaCheckedOn": "2026-09-23",
      "ema": "No record found",
      "emaNote": "No row for this substance in the EMA medicines report generated 22 September 2026. That report does not cover national authorisations in EU member states.",
      "emaSourceUrl": "https://www.ema.europa.eu/en/documents/report/medicines-output-medicines-report_en.xlsx",
      "emaCheckedOn": "2026-09-23",
      "nextMilestone": null,
      "nextMilestoneNote": "No sponsor identified in any record read.",
      "nextMilestoneSourceUrl": null,
      "nextMilestoneCheckedOn": null,
      "sourceUrl": "https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22CJC-1295%22&limit=10",
      "checkedOn": "2026-09-23"
    },
    {
      "compound": "Ipamorelin",
      "compoundId": "ipamorelin",
      "fdaPh": null,
      "fdaPhNote": "Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.",
      "fdaPhSourceUrl": null,
      "fdaPhCheckedOn": null,
      "usFda": "No record found",
      "usFdaNote": "Drugs@FDA returned no approved or tentatively approved application for this substance. Drugs@FDA does not list investigational products. Separately, the FDA lists it on its page of bulk drug substances for compounding that may present significant safety risks (current as of 22 April 2026); that page concerns compounding, not approval.",
      "usFdaSourceUrl": "https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22ipamorelin%22&limit=10",
      "usFdaCheckedOn": "2026-09-23",
      "ema": "No record found",
      "emaNote": "No row for this substance in the EMA medicines report generated 22 September 2026. That report does not cover national authorisations in EU member states.",
      "emaSourceUrl": "https://www.ema.europa.eu/en/documents/report/medicines-output-medicines-report_en.xlsx",
      "emaCheckedOn": "2026-09-23",
      "nextMilestone": null,
      "nextMilestoneNote": "No sponsor identified in any record read.",
      "nextMilestoneSourceUrl": null,
      "nextMilestoneCheckedOn": null,
      "sourceUrl": "https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22ipamorelin%22&limit=10",
      "checkedOn": "2026-09-23"
    },
    {
      "compound": "Bremelanotide",
      "compoundId": "bremelanotide",
      "fdaPh": null,
      "fdaPhNote": "Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.",
      "fdaPhSourceUrl": null,
      "fdaPhCheckedOn": null,
      "usFda": "Approved for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women",
      "usFdaNote": "Drugs@FDA: Vyleesi (NDA210557, approved 21 June 2019). The approval covers the named branded medicine for its labelled use only, never a research-grade vial of the same substance.",
      "usFdaSourceUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210557",
      "usFdaCheckedOn": "2026-09-23",
      "ema": "No record found",
      "emaNote": "No row for this substance in the EMA medicines report generated 22 September 2026. That report does not cover national authorisations in EU member states.",
      "emaSourceUrl": "https://www.ema.europa.eu/en/documents/report/medicines-output-medicines-report_en.xlsx",
      "emaCheckedOn": "2026-09-23",
      "nextMilestone": null,
      "nextMilestoneNote": "None sought: an approved medicine already exists.",
      "nextMilestoneSourceUrl": null,
      "nextMilestoneCheckedOn": null,
      "sourceUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210557",
      "checkedOn": "2026-09-23"
    },
    {
      "compound": "Semax",
      "compoundId": "semax",
      "fdaPh": null,
      "fdaPhNote": "Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.",
      "fdaPhSourceUrl": null,
      "fdaPhCheckedOn": null,
      "usFda": "No record found",
      "usFdaNote": "Drugs@FDA returned no approved or tentatively approved application for this substance. Drugs@FDA does not list investigational products. Separately, the FDA lists it on its page of bulk drug substances for compounding that may present significant safety risks (current as of 22 April 2026); that page concerns compounding, not approval.",
      "usFdaSourceUrl": "https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22semax%22&limit=10",
      "usFdaCheckedOn": "2026-09-23",
      "ema": "No record found",
      "emaNote": "No row for this substance in the EMA medicines report generated 22 September 2026. That report does not cover national authorisations in EU member states.",
      "emaSourceUrl": "https://www.ema.europa.eu/en/documents/report/medicines-output-medicines-report_en.xlsx",
      "emaCheckedOn": "2026-09-23",
      "nextMilestone": null,
      "nextMilestoneNote": "No sponsor identified in any record read.",
      "nextMilestoneSourceUrl": null,
      "nextMilestoneCheckedOn": null,
      "sourceUrl": "https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22semax%22&limit=10",
      "checkedOn": "2026-09-23"
    },
    {
      "compound": "Selank",
      "compoundId": "selank",
      "fdaPh": null,
      "fdaPhNote": "Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.",
      "fdaPhSourceUrl": null,
      "fdaPhCheckedOn": null,
      "usFda": "No record found",
      "usFdaNote": "Drugs@FDA returned no approved or tentatively approved application for this substance. Drugs@FDA does not list investigational products. Separately, the FDA lists it on its page of bulk drug substances for compounding that may present significant safety risks (current as of 22 April 2026); that page concerns compounding, not approval.",
      "usFdaSourceUrl": "https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22selank%22&limit=10",
      "usFdaCheckedOn": "2026-09-23",
      "ema": "No record found",
      "emaNote": "No row for this substance in the EMA medicines report generated 22 September 2026. That report does not cover national authorisations in EU member states.",
      "emaSourceUrl": "https://www.ema.europa.eu/en/documents/report/medicines-output-medicines-report_en.xlsx",
      "emaCheckedOn": "2026-09-23",
      "nextMilestone": null,
      "nextMilestoneNote": "No sponsor identified in any record read.",
      "nextMilestoneSourceUrl": null,
      "nextMilestoneCheckedOn": null,
      "sourceUrl": "https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22selank%22&limit=10",
      "checkedOn": "2026-09-23"
    },
    {
      "compound": "DSIP",
      "compoundId": "dsip",
      "fdaPh": null,
      "fdaPhNote": "Could not be fetched on 23 September 2026: the FDA Philippines verification portal timed out.",
      "fdaPhSourceUrl": null,
      "fdaPhCheckedOn": null,
      "usFda": "No record found",
      "usFdaNote": "Drugs@FDA returned no approved or tentatively approved application for this substance. Drugs@FDA does not list investigational products. Separately, the FDA lists it on its page of bulk drug substances for compounding that may present significant safety risks (current as of 22 April 2026); that page concerns compounding, not approval.",
      "usFdaSourceUrl": "https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22delta%20sleep-inducing%20peptide%22&limit=10",
      "usFdaCheckedOn": "2026-09-23",
      "ema": "No record found",
      "emaNote": "No row for this substance in the EMA medicines report generated 22 September 2026. That report does not cover national authorisations in EU member states.",
      "emaSourceUrl": "https://www.ema.europa.eu/en/documents/report/medicines-output-medicines-report_en.xlsx",
      "emaCheckedOn": "2026-09-23",
      "nextMilestone": null,
      "nextMilestoneNote": "No sponsor identified in any record read.",
      "nextMilestoneSourceUrl": null,
      "nextMilestoneCheckedOn": null,
      "sourceUrl": "https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22delta%20sleep-inducing%20peptide%22&limit=10",
      "checkedOn": "2026-09-23"
    }
  ]
}